EcoDrugPlus

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSCATG00000044144
Gene Symbol: GHSR
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSCATG00000040379
Gene Symbol: GUCY1A1
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSCATG00000037410
Gene Symbol: GUCY1A2
2 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSCATG00000044838
Gene Symbol: GUCY1B1
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSCATG00000035400
Gene Symbol: HSP90AB1
4 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein Hsp 90-Alpha-Like

Ensembl ID : ENSCATG00000011416
Gene Symbol: LOC105588370
1 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

High Mobility Group Box 1

Ensembl ID : ENSCATG00000017216
Gene Symbol: HMGB1
4 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H1

Ensembl ID : ENSCATG00000000316
Gene Symbol: HRH1
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSCATG00000045358
Gene Symbol: HRH2
4 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H3

Ensembl ID : ENSCATG00000028495
Gene Symbol: HRH3
4 Cross references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H4

Ensembl ID : ENSCATG00000031595
Gene Symbol: HRH4
4 Cross references
104 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 1 Pseudogene

Ensembl ID : ENSCATG00000033802
Gene Symbol: LOC105594296
1 Cross references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).